Literature DB >> 29276237

Formulary Drug Review: Etelcalcetide.

Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The November 2017 monograph topics are Ertugliflozin, Glecaprevir / pibrentasvir, Neratinib, Sofosbuvir, velpatasvir, voxilaprevir and SQ C1 esterase inhibitor. The MUE is on glecaprevir, pibrentasvir.

Entities:  

Keywords:  formulary management/P&T; metabolic/endocrine; nephrology

Year:  2017        PMID： 29276237      PMCID： PMC5735746          DOI： 10.1177/0018578717733478

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  14 in total

1.  A pharmacokinetic/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects.

Authors:  Jun Shen; Jim Xiao; Karen Pickthorn; Saling Huang; Gregory Bell; Andrew Vick; Ping Chen
Journal:  J Clin Pharmacol       Date:  2014-05-02       Impact factor: 3.126

2.  Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.

Authors:  Ping Chen; Murad Melhem; Jim Xiao; Mita Kuchimanchi; Juan Jose Perez Ruixo
Journal:  J Clin Pharmacol       Date:  2015-02-18       Impact factor: 3.126

3.  A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients.

Authors:  Gregory Bell; Saling Huang; Kevin J Martin; Geoffrey A Block
Journal:  Curr Med Res Opin       Date:  2015-05       Impact factor: 2.580

4.  Critical Cysteine Residues in Both the Calcium-Sensing Receptor and the Allosteric Activator AMG 416 Underlie the Mechanism of Action.

Authors:  Shawn T Alexander; Thomas Hunter; Sarah Walter; Jin Dong; Derek Maclean; Amos Baruch; Raju Subramanian; James E Tomlinson
Journal:  Mol Pharmacol       Date:  2015-08-19       Impact factor: 4.436

Review 5.  The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.

Authors:  Mariano Rodríguez; William G Goodman; Vassilios Liakopoulos; Piergiorgio Messa; Andrzej Wiecek; John Cunningham
Journal:  Semin Dial       Date:  2015-03-08       Impact factor: 3.455

6.  Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel d-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide).

Authors:  Raju Subramanian; Xiaochun Zhu; Savannah J Kerr; Joel D Esmay; Steven W Louie; Katheryne Z Edson; Sarah Walter; Michael Fitzsimmons; Mylo Wagner; Marcus Soto; Roger Pham; Sarah F Wilson; Gary L Skiles
Journal:  Drug Metab Dispos       Date:  2016-02-19       Impact factor: 3.922

7.  Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.

Authors:  Sarah Walter; Amos Baruch; Jin Dong; James E Tomlinson; Shawn T Alexander; Julie Janes; Tom Hunter; Qun Yin; Derek Maclean; Gregory Bell; Dirk B Mendel; Randolph M Johnson; Felix Karim
Journal:  J Pharmacol Exp Ther       Date:  2013-05-14       Impact factor: 4.030

8.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl       Date:  2009-08       Impact factor: 10.545

9.  Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.

Authors:  Mark R Fielden; Charles Dean; Kurt Black; Satin G Sawant; Raju Subramanian; James E Tomlinson; Sarah Walter; Cameron Zimmermann; Mark W Griggs; Marie E McKeon; Elise M Lewis; Carol Beevers; Ian Pyrah
Journal:  Int J Toxicol       Date:  2016-03-02       Impact factor: 2.032

10.  Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.

Authors:  Kevin J Martin; Gregory Bell; Karen Pickthorn; Saling Huang; Andrew Vick; Peter Hodsman; Munro Peacock
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992
View more
  1 in total

Review 1.  2017 FDA Peptide Harvest.

Authors:  Othman Al Musaimi; Danah Al Shaer; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.